StockNews.AI
WGS
StockNews.AI
29 days

GeneDx Holdings Corp. (NASDAQ: WGS) Investor Alert: Schubert Jonckheer Investigates Possible False Statements and Insider Trading

1. GeneDx is facing legal claims for alleged false statements about Centrellis. 2. A judge ruled that a securities fraud lawsuit can proceed against GeneDx executives. 3. The complaint claims GeneDx misled investors about its technology's capabilities. 4. Insider trading occurred during the period of alleged misleading statements. 5. GeneDx's stock fell 33% after disclosing a business model shift and layoffs.

5m saved
Insight
Article

FAQ

Why Bearish?

Legal investigations can erode investor confidence, similar to past cases affecting stock prices.

How important is it?

The legal claims directly involve WGS's executive conduct and may influence stock valuation.

Why Short Term?

Immediate legal proceedings and potential liabilities can impact stock sentiment in the short term.

Related Companies

LEDSNTRBGENE
, /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises GeneDx Holdings Corp. (NASDAQ: WGS) investors that the firm is investigating potential legal claims relating to alleged false statements about its health intelligence platform called Centrellis. Current shareholders are encouraged to contact the firm. On June 23, 2025, Judge Vernon D. Oliver of the U.S. District Court for the District of Connecticut ruled that a securities fraud lawsuit against GeneDx, its CEO, and former company executives could move forward. The lawsuit alleges that between January 2022 and August 2022, GeneDx (then named Sema4 Holdings Corp.) misled investors by falsely overstating the capabilities, potential, and commercial viability of Centrellis. These statements allegedly caused GeneDx's stock to trade at artificially inflated prices. Judge Oliver found that the complaint sufficiently alleged that the defendants made false and misleading statements regarding Centrellis with an intent to defraud. During this period, various company insiders sold significant amounts of GeneDx stock. After the truth came out in August 2022 that GeneDx was significantly shifting its core R&D strategy and business model, its President was resigning, and the company was cutting 13% of its workforce, GeneDx's stock price fell 33%. We are investigating potential wrongdoing by GeneDx's directors and officers in connection with these allegations. If you own stock in GeneDx, you may have legal options. Visit https://www.classactionlawyers.com/genedxto learn more.About Schubert Jonckheer & Kolbe LLPSchubert Jonckheer & Kolbe represents consumers in class actions against corporate defendants, as well as shareholders in derivative actions against officers and directors. The firm is based in San Francisco and, with the help of co-counsel, litigates cases nationwide.ContactDustin L. Schubert[email protected]Tel: 415-788-4220SOURCE Schubert Jonckheer & Kolbe LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News